The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $246,750 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, to investigate the therapeutic potential of targeting the enzyme OGDH for the treatment of glioblastoma, the most common and aggressive type of brain cancer. The research aims to extend prior findings that OGDH is a critical driver of glioblastoma growth, and will explore the underlying mechanisms and assess whether the standard of care is enhanced by inhibiting OGDH, including appropriate pharmacological analyses. The grant award has a period of performance from April 15, 2024 to March 31, 2026.
Generated 2/25/25, 1:47 AM